Novel mixed polymeric micelles for enhancing delivery of anticancer drug and overcoming multidrug resistance in tumor cell lines simultaneously

Pharmaceutical Research

Volumn 27, Issue 8, 2010, Pages 1498-1511

  Li, Xinru ^a   Li, Pingzhu ^a   Zhang, Yanhui ^a   Zhou, Yanxia ^a   Chen, Xingwei ^a   Huang, Yanqing ^b   Liu, Yan ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b PEKING UNIVERSITY   (China)

Author keywords

methoxy poly(ethylene glycol) poly(D,L lactic acid) (mPEG PLA); mixed polymeric micelles; multidrug resistance (MDR); paclitaxel; pluronic L61

Indexed keywords

MACROGOL; PACLITAXEL; POLOXAMER; POLYLACTIC ACID; ANTINEOPLASTIC AGENT; MACROGOL DERIVATIVE; METHOXY POLY(ETHYLENE GLYCOL)-POLY(LACTIDE); MICELLE; PLURONIC L61; POLYESTER;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CANCER CELL CULTURE; CELL MEMBRANE FLUIDITY; CELL STRAIN MCF 7; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CRITICAL MICELLE CONCENTRATION; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG PENETRATION; DRUG SOLUBILITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; MALE; MEAN RESIDENCE TIME; MICELLE; MULTIDRUG RESISTANCE; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RAT; ANIMAL; BREAST NEOPLASMS; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RESISTANCE; FEMALE; IC50; PARTICLE SIZE; SPRAGUE DAWLEY RAT; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; MICELLES; PACLITAXEL; PARTICLE SIZE; POLOXAMER; POLYESTERS; POLYETHYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 77955469304     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-010-0147-1     Document Type: Article

References (70)

1. WD Stein SE Bates T Fojo 2004 Intractable cancers: the many faces of multidrug resistance and the many targets it presents for therapeutic attack Curr Drug Targets 5 333 46 10.2174/1389450043345489 15134216 (Pubitemid 38559343)
2. SK Calderwood MA Khaleque DB Sawyer DR Ciocca 2006 Heat shock proteins in cancer: chaperones of tumorigenesis Trends Biochem. Sci. 31 164 72 10.1016/j.tibs.2006.01.006 16483782 (Pubitemid 43361923)
3. V Kirkin S Joos M Zornig 2004 The role of Bcl-2 family members in tumorigenesis Biochim Biophys Acta. 1644 229 49 10.1016/j.bbamcr.2003.08.009 14996506 (Pubitemid 38281277)
4. G Szakacs JK Paterson JA Ludwig C Booth-Genthe MM Gottesman 2006 Targeting multidrug resistance in cancer Nat Rev Drug Discov. 5 219 34 10.1038/nrd1984 16518375 (Pubitemid 43336035)
5. C Duhem F Ries M Dicato 1996 What does Multidrug Resistance (MDR) expression mean in the clinic? Oncologist 1 151 8 10387981
6. MM Gottesman T Fojo SE Bates 2002 Multidrug resistance in cancer: Role of ATP-dependent transporters Nat Rev Cancer. 2 48 58 10.1038/nrc706 11902585
7. MM Gottesman I Pastan SV Ambudkar 1996 P-glycoprotein and multi drug resistance Curr Opin Genet Dev. 6 610 7 10.1016/S0959-437X(96)80091-8 8939727 (Pubitemid 26372158)
8. H Lage 2006 MDR1/P-glycoprotein (ABCB1) as target for RNA interference-mediated reversal of multidrug resistance Curr Drug Targets. 7 813 21 10.2174/138945006777709566 16842213
9. DR Ferry H Traunecker DJ Kerr 1996 Clinical trials of P-glycoprotein reversal in solid tumours Eur J Cancer 32A 1070 81 10.1016/0959-8049(96)00091-3 8763349
10. R Krishna LD Mayer 2000 Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs Eur J Pharm Sci. 11 265 83 10.1016/S0928-0987(00)00114-7 11033070
11. EK Rowinsky L Smith YM Wang P Chaturvedi M Villalona E Campbell, et al. 1998 Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP J Clin Oncol. 16 2964 76 9738565
12. H Thomas HM Coley 2003 Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein Cancer Control 10 159 65 12712010
13. M Werle 2008 Natural and synthetic polymers as inhibitors of drug efflux pumps Pharm. Res. 25 500 11 10.1007/s11095-007-9347-8 17896100
14. A Kabanov V Alakhov 2002 Pluronic block copolymers in drug delivery: from micellar nanocontainers to biological response modifiers Crit Rev Ther Drug Carr Syst. 19 1 72 10.1615/CritRevTherDrugCarrierSyst.v19.i1.10 (Pubitemid 34521248)
15. AK Sharma L Zhang S Li DL Kelly VY Alakhov EV Batrakova, et al. 2008 Prevention of MDR development in leukemia cells by micelle-forming polymeric surfactant J Control Release 131 220 7 10.1016/j.jconrel.2008.07.031 18722489
16. AV Kabanov EV Batrakova VY Alakhov 2002 Pluronic block copolymers for overcoming drug resistance in cancer Adv Drug Deliv Rev. 54 759 79 10.1016/S0169-409X(02)00047-9 12204601 (Pubitemid 35247525)
17. A Venne S Li R Mandeville A Kabanov V Alakhov 1996 Hypersensitizing effect of pluronic L61 on cytotoxic activity, transport, and subcellular distribution of doxorubicin in multiple drug-resistant cells Cancer Res. 56 3626 9 8705995
18. V Alakhov E Moskaleva EV Batrakova AV Kabanov 1996 Hypersensitization of multidrug resistant human ovarian carcinoma cells by pluronic P85 block copolymer Bioconjug Chem. 7 209 16 10.1021/bc950093n 8983343 (Pubitemid 3043439)
19. EV Batrakova S Li VYu Alakhov WF Elmquist DW Miller AV Kabanov 2003 Sensitization of cells overexpressing multidrug-resistant proteins by Pluronic P85 Pharm Res. 20 1581 90 10.1023/A:1026179132599 14620511 (Pubitemid 37268272)
20. EV Batrakova S Li WF Elmquist DW Miller VY Alakhov AV Kabanov 2001 Mechanism of sensitization of MDR cancer cells by Pluronic block copolymers: Selective energy depletion Br J Cancer 85 1987 97 10.1054/bjoc.2001.2165 11747344
21. M Werle 2008 Natural and synthetic polymers as inhibitors of drug efflux pumps Pharm Res. 25 500 11 10.1007/s11095-007-9347-8 17896100
22. K Kataoka A Harada Y Nagasaki 2001 Block copolymer micelles for drug delivery: Design, characterization and biological significance Adv Drug Deliv Rev. 47 113 31 10.1016/S0169-409X(00)00124-1 11251249 (Pubitemid 32209236)
23. H Ai C Flask B Weinberg X Shuai MD Pagel D Farrell, et al. 2005 Magnetite-loaded polymeric micelles as ultrasensitive magnetic-resonance probe Adv Mater. 17 1949 52 10.1002/adma.200401904 (Pubitemid 41206143)
24. SR Croy GS Kwon 2006 Polymeric micelles for drug delivery Curr Pharm Design. 12 4669 84 10.2174/138161206779026245 (Pubitemid 44835136)
25. D Le Garrec S Gori L Luo D Lessard DC Smith M-A Yessine, et al. 2004 Poly(N-vinylpyrrolidone)-block-poly(D, L-lactide) as a new polymeric solubilizer for hydrophobic anticancer drugs: in vitro and in vivo evaluation J Control Release 99 83 101 10.1016/j.jconrel.2004.06.018 15342183 (Pubitemid 39165736)
26. RG Strickley 2004 Solubilizing excipients in oral and injectable formulations Pharm. Res. 21 201 30 10.1023/B:PHAM.0000016235.32639.23 15032302 (Pubitemid 38221966)
27. GS Kwon 2003 Polymeric micelles for delivery of poorly water-soluble compounds Crit Rev Therap Drug Carrier Syst. 20 357 403 10.1615/ CritRevTherDrugCarrierSyst.v20.i5.20 (Pubitemid 38129592)
28. G Barratt 2003 Colloidal drug carriers: achievements and perspectives Cell Mol Life Sci. 60 21 37 10.1007/s000180300002 12613656 (Pubitemid 36223115)
29. S Danson D Ferry V Alakhov J Margison D Kerr D Jowle, et al. 2004 Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer Br J Cancer. 90 2085 91 15150584
30. Y Matsumura T Hamaguchi T Ura K Muro Y Yamada Y Shimada, et al. 2004 Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin Br J Cancer 91 1775 81 10.1038/sj.bjc.6602204 15477860 (Pubitemid 39664964)
31. Y Mizumura Y Matsumura M Yokoyama T Okano T Kawaguchi F Moriyasu, et al. 2002 Incorporation of the anticancer agent KRN5500 into polymeric micelles diminishes the pulmonary toxicity Jpn J Cancer Res. 93 1237 43 12460465
32. XC Zhang HM Burt DV Hoff D Dexter G Mangold D Degen, et al. 1997 An investigation of the antitumor activity and biodistribution of polymeric micellar paclitaxel Cancer Chemother Pharmacol. 40 81 6 10.1007/s002800050630 9137535 (Pubitemid 27160966)
33. X Li Y Huang X Chen Y Zhou Y Zhang P Li, et al. 2009 Self-assembly and characterization of Pluronic P105 micelles for liver-targeted delivery of silybin J Drug Target. 17 739 50 10.3109/10611860903062062 19863195
34. XQ Yang WJ Deng LW Fu E Blanco JM Gao DP Quan, et al. 2008 Folate-functionalized polymeric micelles for tumor targeted delivery of a potent multidrug-resistance modulator FG020326 J Biomed Mater Res. 86A 48 60 10.1002/jbm.a.31537 (Pubitemid 351799487)
35. YZ Wang L Yu LM Han XY Sha XL Fang 2007 Difunctional Pluronic copolymer micelles for paclitaxel delivery: Synergistic effect of folate-mediated targeting and Pluronic-mediated overcoming multidrug resistance in tumor cell lines Inter J Pharm. 337 63 73 10.1016/j.ijpharm.2006.12.033 (Pubitemid 46756036)
36. DA Chiappetta A Sosnik 2007 Poly(ethylene oxide)-poly(propylene oxide) block copolymer micelles as drug delivery agents: Improved hydrosolubility, stability and bioavailability of drugs Eur J Pharm Biopharm. 66 303 17 10.1016/j.ejpb.2007.03.022 17481869 (Pubitemid 46756232)
37. AK Singla A Garg D Aggarwal 2002 Paclitaxel and its formulations Inter J Pharm. 235 179 92 10.1016/S0378-5173(01)00986-3 (Pubitemid 34185449)
38. H Gelderblom J Verweij K Nooter A Sparreboom 2001 Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation Eur J Cancer 37 1590 8 10.1016/S0959-8049(01)00171-X 11527683 (Pubitemid 32778603)
39. RB Weiss RC Donehower PH Wiernik T Ohnuma RJ Gralla DL Trump, et al. 1990 Hypersensitivity reactions from taxol J Clin Oncol. 8 1263 8 1972736
40. R Geney M Ungureanu D Li I Ojima 2002 Overcoming multidrug resistance in taxane chemotherapy Clin Chem Lab Med. 40 918 25 10.1515/CCLM.2002.161 12435109
41. X Zhang JK Jackson HM Burt 1996 Development of amphiphilic diblock copolymers as micellar carriers of taxol Inter J Pharm. 132 195 206 10.1016/0378-5173(95)04386-1 (Pubitemid 26158719)
42. SC Kim DW Kim YH Shim JS Bang HS Oh SW Kim, et al. 2001 In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy J Control Release 72 191 202 10.1016/S0168-3659(01)00275-9 11389998 (Pubitemid 32522357)
43. ZL Yang XR Li KW Yang Y Liu 2008 Amphotericin B-loaded poly(ethylene glycol)-poly(lactide) micelles: Preparation, freeze-drying and in vitro release J Biomed Mater Res. 85A 539 46 10.1002/jbm.a.31504 (Pubitemid 351535336)
44. M Wilhelm CL Zhao YC Wang RL Xu MA Winnik 1999 Macromolecules. 24 1033 40 10.1021/ma00005a010
45. KM Huh SC Lee YW Cho J Lee JH Jeong K Park 2005 Hydrotropic polymer micelle system for delivery of paclitaxel J Control Release 101 59 68 10.1016/j.jconrel.2004.07.003 15588894 (Pubitemid 39600972)
46. E Batrakova S Lee S Li A Venne V Alakhov A Kabanov 1999 Fundamental relationships between the composition of pluronic block copolymers and their hypersensitization effect in MDR cancer cells Pharm Res. 16 1373 9 10.1023/A:1018942823676 10496652 (Pubitemid 29449373)
47. MC Jones JC Leroux 1999 Polymeric micelles-a new generation of colloidal drug carriers Eur J Pharm Biopharm. 48 101 11 10.1016/S0939-6411(99)00039-9 10469928 (Pubitemid 29401986)
48. YW Choa J Leeb SC Leeb KM Huhb K Park 2004 Hydrotropic agents for study of in vitro paclitaxel release from polymeric micelles J Control Release 97 249 57 10.1016/j.jconrel.2004.03.013 (Pubitemid 38759482)
49. SC Lee C Kim IC Kwon H Chung SY Jeong 2003 Polymeric micelles of poly(2-ethyl-2-oxazoline)-block-poly(ε-caprolactone) copolymer as a carrier for paclitaxel J Control Release 89 437 46 10.1016/S0168-3659(03)00162-7 (Pubitemid 36555903)
50. E Friche PB Jensen M Sehested EF Demant NN Nissen 1990 The solvents Cremophor EL and Tween 80 modulate daunorubicin resistance in the multidrug resistant Ehrlich ascites tumor Cancer Commun. 2 297 303 1976341 (Pubitemid 20380453)
51. M Hwang C-H Ahn PS Pine JJ Yin CA Hrycyna T Licht, et al. 1996 Effect of combination of suboptimal concentrations of P-glycoprotein blockers on the proliferation of MDR1 gene expressing cells Int J Cancer 65 389 97 10.1002/(SICI)1097-0215(19960126)65:3<389::AID-IJC19>3.0.CO;2-5 8575863 (Pubitemid 26059991)
52. TA Brasitus 1992 Modulation of P-glycoprotein-mediated drug transport by alterations in lipid fluidity of rat liver canalicular membrane vesicles J Biol Chem. 267 24995 5002 1360981
53. PK Dudeja KM Anderson JS Harris L Buckingham JS Coon 1995 Reversal of multidrug resistance phenotype by surfactants: relationship to membrane lipid fluidity Arch Biochem Biophys. 319 309 15 10.1006/abbi.1995.1298 7771801
54. L Webster M Linsenmeyer M Millward C Morton J Bishop D Woodcock 1993 Measurement of CrEL following Taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype J Natl Cancer Inst. 85 1685 90 10.1093/jnci/85.20.1685 8105099
55. LK Webster ME Linsenmeyer D Rischin ME Urch DM Woodcock MJ Millward 1997 Plasma concentrations of polysorbate 80 measured in patients following administration of docetaxel or etoposide Cancer Chemother Pharmacol. 39 557 60 10.1007/s002800050615 9118471 (Pubitemid 27096775)
56. AL Arsenaut V Ling N Kartner 1988 Altered plasma membrane ultrastructure in multidrug resistant cells Bichim Biophys Acta. 938 315 21 10.1016/0005-2736(88)90169-1
57. EV Batrakova DW Miller S Li VY Alakhov AV Kabanov WF Elmquist 2001 Pluronic P85 enhances the delivery of digoxin to the brain: in vitro and in vivo studies J Pharmacol Exp Ther. 296 551 11160643
58. R Evers M Kool AJ Smith LV Deemter MD Haas P Borst 2000 Inhibitory effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1- and MRP2-mediated transport Br J Cancer 83 366 74 10.1054/bjoc.2000.1260 10917553
59. S Naito H Koga A Yokomizo N Sakamoto S Kotoh M Nakashima, et al. 2000 Molecular analysis of mechanisms regulating drug sensitivity and the development of newchemotherapy strategies for genitourinary carcinomas World J. Surg. 24 1183 6 10.1007/s002680010200 11071457
60. AT Fojo K Ueda DJ Slamon DG Poplack MM Gottesman I Pastan 1987 Expression of a multidrug-resistance gene in human tumors and tissues Proc Natl Acad Sci USA. 84 265 9 10.1073/pnas.84.1.265 2432605 (Pubitemid 17013615)
61. DM van der Kolk EG de Vries WJ van Putten LF Verdonck GJ Ossenkoppele GE Verhoef, et al. 2000 P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia Clin Cancer Res. 6 3205 14 10955805
62. T Fojo S Bates 2003 Strategies for reversing drug resistance Oncogene 22 7512 23 10.1038/sj.onc.1206951 14576855 (Pubitemid 37487173)
63. EV Batrakova TY Dorodnych EY Klinskii EN Kliushnenkova OB Shemchukova ON Goncharova, et al. 1996 Anthracycline antibiotics non-covalently incorporated into the block copolymer micelles: in vivo evaluation of anti-cancer activity Br J Cancer. 74 1545 52 8932333
64. V Alakhov E Klinski S Li G Pietrzynski A Venne EV Batrakova, et al. 1999 Block copolymer-based formulation of doxorubicin. From cell screen to clinical trials Colloids Surf B Biointerfaces 16 113 34 10.1016/S0927-7765(99)00064-8 (Pubitemid 29486800)
65. T Kitazaki M Oka Y Nakamura J Tsurutani S Doi M Yasunaga, et al. 2005 Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells Lung Cancer 49 337 43 10.1016/j.lungcan.2005.03.035 15955594 (Pubitemid 41139146)
66. EV Batrakova H-Y Han VYu Alakhov DW Miller AV Kabanov 1998 Effects of Pluronic block copolymers on drug absorption in Caco-2 cell monolayers Pharm Res. 15 850 5 10.1023/A:1011964213024 9647349 (Pubitemid 28307825)
67. DW Miller EV Batrakova TO Waltner VYu Alakhov AV Kabanov 1997 Interaction of Pluronic block copolymers with brain microvessel endothelial cells: evidence for multiple absorption pathways Bioconjugate Chem. 8 649 57 10.1021/bc970118d (Pubitemid 27416077)
68. EV Batrakova H-Y Han DW Miller AV Kabanov 1998 Effects of Pluronic P85 unimers and micelles on drug permeability in polarized BBMEC and Caco-2 cells Pharm Res. 15 1525 32 10.1023/A:1011942814300 9794493 (Pubitemid 28465737)
69. F Mathot 2007 A. des Rieux, A. Arien, Y.J. Schneider, M. Brewster, V. Preat. Transport mechanisms of mmePEG750P(CL-co-TMC) polymeric micelles across the intestinal barrier J Control Release 124 134 43 10.1016/j.jconrel.2007.09. 001 17928087 (Pubitemid 350110487)
70. RT Liggins HM Burt 2002 Polyether-polyester diblock copolymers for the preparation of paclitaxel loaded polymeric micelle formulations Adv Drug Deliv Rev. 54 191 202 10.1016/S0169-409X(02)00016-9 11897145 (Pubitemid 34230441)